Abstract 2927
Background
Cancer, which is included in the scope of chronic diseases, affects the lifestyle and quality of the individuals, who got diagnosed, and their familes due to the disease course and treatment method. According to the "theory of family systems", when a disease occurs in the individual, the whole family is affected by the disease, not only patient. It is suggested that families should not be seen as a passive shelter for patients, they should also as a human unity living at the same time as the cancer crisis. In cancer care, caregivers have many responsibilities, from diagnosis to the end of life. While there are studies conducted to evaluate the quality of life of cancer patients in Turkey and other countries, there are a limited number of studies evaluating the quality of life of caregivers of cancer patients. It was aimed to performed in our country for validity and reliability of "Singapore Caregiver Quality Of Life Scale", which was planned based on this deficiency, and to be a guide for the evaluation of the quality of the life of the relatives or carers of different cultures, different ethnic groups and determining the nursing care strategies.
Methods
This study, which was planned as a methodological and descriptive study, was caried out with 550 caregivers in two university hospitals in Izmir. The data were collected by using the Individual Presentation Form, Singapore Caregiver Quality of Life Scale and Quality of Life Scale in Cancer Patients Family Version. Written informed consent was obtained from hospitals and individuals.
Results
The analysis of the findings is ongoing and will be shared in the full text.
Conclusions
Quality of life of caregivers of cancer patients is an important indicator of the quality of life of the patient. In this study, Turkish validation sfudies of the "Singapore Caregiver Quality Of Life Scale" were conducted. The results will be shared later.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2108 - Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase 3 study.
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3090 - Comparison of Immuno-Oncology (IO) Biomarkers in Adenocarcinoma (ACB), Urothelial Carcinoma (UCB) and Squamous Cell Carcinoma (SCCB) of the Bladder, with interim results from PURE01
Presenter: Daniele Raggi
Session: Poster Display session 3
Resources:
Abstract
5211 - Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients
Presenter: Albert Font
Session: Poster Display session 3
Resources:
Abstract
3206 - Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Anti-tumor Activity Among Patients (Pts) with Advanced Urothelial Carcinoma (UC)
Presenter: Scott Tagawa
Session: Poster Display session 3
Resources:
Abstract
3110 - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting
Presenter: Florian Roghmann
Session: Poster Display session 3
Resources:
Abstract
3564 - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)
Presenter: Jean-Michel Lavoie
Session: Poster Display session 3
Resources:
Abstract
2760 - Comparative analysis of tumor mutational burden (TMB) prediction methods and its association with determinants of the tumor immune microenvironment of urothelial bladder cancer (UBC)
Presenter: Markus Eckstein
Session: Poster Display session 3
Resources:
Abstract
2513 - The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival
Presenter: Elise Nassif
Session: Poster Display session 3
Resources:
Abstract
2835 - Genomic analysis of urothelial cancer and associations with treatment choice and outcome
Presenter: David Sarid
Session: Poster Display session 3
Resources:
Abstract
5763 - cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Presenter: Sumanta Pal
Session: Poster Display session 3
Resources:
Abstract